+Compare
IMRN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
12.59M

IMRN Immuron Limited Forecast, Technical & Fundamental Analysis

a biopharmaceutical company

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for IMRN with price predictions
07:00 PM EST Dec 06, 2023

IMRN in upward trend: 10-day moving average crossed above 50-day moving average on November 27, 2023

The 10-day moving average for IMRN crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2023. You may want to consider a long position or call options on IMRN as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMRN just turned positive on November 13, 2023. Looking at past instances where IMRN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

IMRN moved above its 50-day moving average on November 24, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRN advanced for three days, in of 156 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IMRN moved out of overbought territory on December 01, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMRN broke above its upper Bollinger Band on November 14, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMRN entered a downward trend on November 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.896) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (9.737) is also within normal values, averaging (330.425).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 25%. IVBT experienced the highest price growth at 1,413%, while AMPE experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -58%. For the same stocks of the Industry, the average monthly volume growth was -53% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Chapman Street
Phone
+61 398245254
Employees
6
Web
https://www.immuron.com.au
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FTDR35.280.30
+0.86%
Frontdoor
CDXS2.190.01
+0.69%
Codexis
KRUS61.190.40
+0.66%
Kura Sushi USA
CMS57.940.11
+0.19%
CMS Energy Corp
CNSP2.08-0.02
-0.95%
CNS Pharmaceuticals

IMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRN has been loosely correlated with TRVN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRN jumps, then TRVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRN
1D Price
Change %
IMRN100%
-2.38%
TRVN - IMRN
34%
Loosely correlated
+0.59%
JAGX - IMRN
24%
Poorly correlated
-10.16%
PHAR - IMRN
24%
Poorly correlated
+5.55%
APLMW - IMRN
23%
Poorly correlated
+43.31%
AIM - IMRN
22%
Poorly correlated
+11.55%
More

Groups containing IMRN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRN
1D Price
Change %
IMRN100%
-2.38%
australia
(undefined stocks)
18%
Poorly correlated
-1.42%
biopharmaceuticals
(undefined stocks)
14%
Poorly correlated
+0.74%
biotechnology
(undefined stocks)
11%
Poorly correlated
+0.64%
drugs
(undefined stocks)
9%
Poorly correlated
+0.88%